DeepMed Research

ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Histological and Microbiological Evaluation of Late Occurring Nodules With Hyaluronic Acid Dermal Fillers

Completed

Conditions: Dermal Nodule

Interventions: Other: No Intervention

First Posted Date: 2018-02-08

Last Posted Date: 2021-08-06

Lead Sponsor: Allergan

Target Recruit Count: 17

Registration Number: NCT03425721

Locations: 🇺🇸
Assure Surgical, P.C., New York, New York, United States
🇺🇸
Skin Care and Laser Physicians (SCLP) of Beverly Hills, West Hollywood, California, United States

Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour

Phase 4

Completed

Conditions: Contour

Interventions: Drug: BELKYRA®
Device: Juvéderm® VOLUMA™ with Lidocaine

First Posted Date: 2018-02-07

Last Posted Date: 2020-12-31

Lead Sponsor: Allergan

Target Recruit Count: 58

Registration Number: NCT03425253

Locations: 🇦🇺
Living Art, East Melbourne, Victoria, Australia
🇦🇺
Darlinghurst Dermatology, Darlinghurst, New South Wales, Australia
🇦🇺
Dermatology Institute of Victoria, South Yarra, Victoria, Australia

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

Phase 3

Terminated

Conditions: Gastroparesis
Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Relamorelin

First Posted Date: 2018-02-05

Last Posted Date: 2021-12-22

Lead Sponsor: Allergan

Target Recruit Count: 467

Registration Number: NCT03420781

Locations: 🇺🇸
Gastroenterology Associates of Fairfield County, P.C., Bridgeport, Connecticut, United States
🇺🇸
Applied Research Center of Arkansas, Little Rock, Arkansas, United States
🇺🇸
Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States

and more 329 locations

A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel to Correct Infraorbital Hollowing

Phase 3

Completed

Conditions: Infraorbital Hollowing

Interventions: Device: JUVÉDERM VOLBELLA® XC injectable gel

First Posted Date: 2018-02-01

Last Posted Date: 2021-11-15

Lead Sponsor: Allergan

Target Recruit Count: 163

Registration Number: NCT03418545

Locations: 🇺🇸
Steve Yoelin MD Medical Associate, Inc., Newport Beach, California, United States
🇺🇸
Cosmetic Laser Dermatology, San Diego, California, United States
🇺🇸
Facesplus, Inc., San Diego, California, United States

and more 12 locations

Physiopathologic Aspects and Quality of Life in Participants With Eye Dark Circles

Completed

Conditions: Periorbital Hyperpigmentation

Interventions: Device: Skin imaging
Other: Facial cleanser

First Posted Date: 2018-01-17

Last Posted Date: 2019-01-23

Lead Sponsor: Allergan

Target Recruit Count: 44

Registration Number: NCT03400202

Locations: 🇺🇸
SkinMedica Clinical Research and Innovation Center, Irvine, California, United States

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

Phase 3

Terminated

Conditions: Gastroparesis
Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Relamorelin

First Posted Date: 2017-12-26

Last Posted Date: 2021-11-23

Lead Sponsor: Allergan

Target Recruit Count: 450

Registration Number: NCT03383146

Locations: 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸
Endocrinology Research Associates, Inc., Columbus, Ohio, United States
🇺🇸
Texas Clinical Research Institute, LLC, Arlington, Texas, United States

and more 331 locations

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Cenicriviroc

First Posted Date: 2017-12-19

Last Posted Date: 2018-01-11

Lead Sponsor: Allergan

Target Recruit Count: 16

Registration Number: NCT03376841

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States

Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma

Phase 3

Completed

Conditions: Angle-Closure
Glaucoma

Interventions: Device: XEN45

First Posted Date: 2017-12-05

Last Posted Date: 2023-05-17

Lead Sponsor: Allergan

Target Recruit Count: 65

Registration Number: NCT03362931

Locations: 🇸🇬
Tan Tock Seng Hospital /ID# 233014, Singapore, Singapore
🇨🇳
Buddhist Tzu Chi General Hospital /ID# 232664, Hualien, Taiwan
🇸🇬
Nuh Medical Centre /ID# 232905, Singapore, Singapore

and more 13 locations

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD

Phase 1

Completed

Conditions: Macular Degeneration

Interventions: Drug: Abicipar pegol

First Posted Date: 2017-11-08

Last Posted Date: 2018-11-01

Lead Sponsor: Allergan

Target Recruit Count: 11

Registration Number: NCT03335852

Locations: 🇯🇵
Takeuchi Eye Clinic, Taito-ku, Tokyo, Japan
🇯🇵
Kimura Eye and Internal Medicine Hospital, Kure, Hiroshima, Japan
🇯🇵
Musashi Dream Clinic, Tennouji-ku, Osaka, Japan

and more 2 locations

Clinical Trial to Evaluate the Symptoms in Symptomatic Contact Lens Wearers Following Application of Intranasal Tear Neurostimulator Versus Control

Not Applicable

Completed

Conditions: Dry Eye Syndromes

Interventions: Device: TrueTear Sham Control
Device: TrueTear

First Posted Date: 2017-10-30

Last Posted Date: 2019-12-18

Lead Sponsor: Allergan

Target Recruit Count: 84

Registration Number: NCT03325673

Locations: 🇨🇦
Centre for Contact Lens Research School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy